Synergistic antitumor activity of sorafenib and the NUPR1 inhibitor LZX-2-73 in multiple cancer models
9.5
来源：
Nature
关键字：
AI medical imaging
发布时间：
2025-11-18 03:37
摘要：
The study reveals that the combination of sorafenib, an FDA-approved multi-targeted kinase inhibitor, and LZX-2-73, a novel NUPR1 inhibitor, exhibits strong synergistic anticancer effects across multiple cancer models, particularly in pancreatic cancer. This combination enhances therapeutic efficacy by inducing oxidative stress and promoting cell death, offering a promising strategy to overcome drug resistance in cancer treatment. The findings suggest that targeting NUPR1 could broaden the clinical application of sorafenib and improve outcomes for cancer patients.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分+1.0分=2.0分
business_impact
1.0分+1.0分=2.0分
scientific_rigor
1.5分+1.5分=3.0分
timeliness_innovation
1.5分+1.5分=3.0分
investment_perspective
2.5分+2.5分=5.0分
market_value_relevance
1.0分+1.0分=2.0分
team_institution_background
0.5分+0.5分=1.0分
technical_barrier_competition
1.0分+1.0分=2.0分
关键证据
Combination of LZX-2-73 and sorafenib led to substantial increase in cell death due to massive oxidative stress.
The study provides valuable insights into enhancing anticancer activity through combination therapy.
LZX-2-73 demonstrates potent anticancer activity, targeting the nuclear protein 1 (NUPR1).
真实性检查
否
AI评分总结
The study reveals that the combination of sorafenib, an FDA-approved multi-targeted kinase inhibitor, and LZX-2-73, a novel NUPR1 inhibitor, exhibits strong synergistic anticancer effects across multiple cancer models, particularly in pancreatic cancer. This combination enhances therapeutic efficacy by inducing oxidative stress and promoting cell death, offering a promising strategy to overcome drug resistance in cancer treatment. The findings suggest that targeting NUPR1 could broaden the clinical application of sorafenib and improve outcomes for cancer patients.